PG
ABBV icon

Prostatis Group’s AbbVie ABBV Stock Holding History

Prostatis Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437K Buy
1,736
+118
+7% +$25.4K 0.1% 116
2026
Q1 		$352K Buy
1,618
+95
+6% +$21.1K 0.09% 123
2025
Q4 		$348K Sell
1,523
-14
-0.9% -$3.19K 0.08% 123
2025
Q3 		$356K Sell
1,537
-14
-0.9% -$2.85K 0.09% 112
2025
Q2 		$288K Buy
1,551
+88
+6% +$16.4K 0.08% 122
2025
Q1 		$307K Buy
1,463
+29
+2% +$5.64K 0.1% 118
2024
Q4 		$255K Sell
1,434
-87
-6% -$16K 0.07% 138
2024
Q3 		$300K Sell
1,521
-89
-6% -$16.6K 0.1% 112
2024
Q2 		$276K Buy
1,610
+89
+6% +$14.7K 0.1% 122
2024
Q1 		$277K Buy
1,521
+25
+2% +$4.31K 0.11% 119
2023
Q4 		$232K Buy
1,496
+61
+4% +$8.89K 0.1% 119
2023
Q3 		$214K Sell
1,435
-62,081
-98% -$9.11M 0.1% 106
2023
Q2 		$197K Buy
63,516
+62,085
+4,339% +$9.1M 0.09% 109
2023
Q1 		$215K Sell
1,431
-10
-0.7% -$1.53K 0.11% 93
2022
Q4 		$233K Buy
+1,441
New +$221K 0.14% 88

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Prostatis Group's ABBV Position: Q2 2026 in Review

Prostatis Group increased its AbbVie (ABBV) stake by 7.3% in Q2 2026, buying an estimated $25.4K and bringing the position to 1,736 shares worth $437K. The position accounts for 0.1% of the portfolio, ranked #116.

Prostatis Group first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Prostatis Group held 1,736 shares of AbbVie worth $437K as of Q2 2026.
  • Prostatis Group bought 118 AbbVie shares in Q2 2026, an estimated $25.4K.
  • AbbVie made up 0.1% of Prostatis Group's portfolio in Q2 2026, its #116 holding.
  • Prostatis Group first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.